Subcutaneous interleukin-4 (IL-4) for relapsed and resistant non-Hodgkin lymphoma: A phase II trial in the North Central Cancer Treatment Group, NCCTG 91-78-51
暂无分享,去创建一个
D. Kurtz | K. Rowland | S. Geyer | T. Witzig | G. Soori | Paul J. Kurtin | M. Wiesenfeld | L. Tschetter | J. Allred | W. D. Putnam | R. Tenglin | A. Bernath
[1] G. Saglio,et al. Molecular pathogenesis of diffuse large B-cell lymphoma , 2009 .
[2] Xiaocheng Wu,et al. Annual report to the nation on the status of cancer, 1975–2003, featuring cancer among U.S. Hispanic/Latino populations , 2006, Cancer.
[3] M. Schiller,et al. Interleukin‐4 supports interleukin‐12‐induced proliferation and interferon‐γ secretion in human activated lymphoblasts and T helper type 1 cells , 2006, Immunology.
[4] Randy D Gascoyne,et al. Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[5] S. Galli,et al. Interleukin‐4‐triggered, STAT6‐dependent production of a factor that induces mouse mast cell apoptosis , 2006, European journal of immunology.
[6] L. Ricci-Vitiani,et al. Autocrine production of interleukin-4 and interleukin-10 is required for survival and growth of thyroid cancer cells. , 2006, Cancer research.
[7] I. Soubeyran,et al. Aggressive non-Hodgkin's lymphoma: Concomitant evaluation of interleukin-2, soluble interleukin-2 receptor, interleukin-4, interleukin-6, interleukin-10 and correlation with outcome , 2006, Leukemia & lymphoma.
[8] R. Puri,et al. A recombinant IL-4-Pseudomonas exotoxin inhibits protein synthesis and overcomes apoptosis resistance in human CLL B cells. , 2005, Leukemia research.
[9] Ash A. Alizadeh,et al. Distinct IL-4-induced gene expression, proliferation, and intracellular signaling in germinal center B-cell-like and activated B-cell-like diffuse large-cell lymphomas. , 2005, Blood.
[10] R. Marcus,et al. CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma. , 2005, Blood.
[11] I. Lossos,et al. IL-4 Affects Proliferation, Chemosensitivity-and Rituximab Sensitivity of Germinal Center B-Cell like (GCB) and Activated B-Cell like (ABC) Diffuse Large B-Cell Lymphoma Differently. , 2004 .
[12] Yusuke Nakamura,et al. Identification of the interleukin 4 receptor alpha gene as a direct target for p73. , 2003, Cancer research.
[13] Robert Tibshirani,et al. HGAL is a novel interleukin-4-inducible gene that strongly predicts survival in diffuse large B-cell lymphoma. , 2003, Blood.
[14] B. E. C. Oiffier,et al. CHOP Chemotherapy plus Rituximab Compared with CHOP Alone in Elderly Patients with Diffuse Large-B-Cell Lymphoma , 2002 .
[15] I. Pastan,et al. IL-4 receptors on human medulloblastoma tumours serve as a sensitive target for a circular permuted IL-4-Pseudomonas exotoxin fusion protein , 2002, British Journal of Cancer.
[16] J. Bertoglio,et al. Induction of the IL-13 receptor α2-chain by IL-4 and IL-13 in human keratinocytes: involvement of STAT6, ERK and p38 MAPK pathways , 2001, Oncogene.
[17] H M Rosenberg,et al. Annual report to the nation on the status of cancer (1973 through 1998), featuring cancers with recent increasing trends. , 2001, Journal of the National Cancer Institute.
[18] R. Fisher,et al. Phase II evaluation of interleukin-4 in patients with non-Hodgkin's lymphoma: a Southwest Oncology Group Trial , 2000, Anti-cancer drugs.
[19] P. Rothman,et al. IL-4/IL-13 signaling beyond JAK/STAT. , 2000, The Journal of allergy and clinical immunology.
[20] I. Pastan,et al. Interleukin-4 receptor-directed cytotoxin therapy of AIDS-associated Kaposi's sarcoma tumors in xenograft model , 1999, Nature Medicine.
[21] J. Ritz,et al. The functional synergy between IL-12 and IL-2 involves p38 mitogen-activated protein kinase and is associated with the augmentation of STAT serine phosphorylation. , 1999, Journal of immunology.
[22] J. Gustafsson,et al. Extracellular signal-regulated kinase (ERK) interacts with signal transducer and activator of transcription (STAT) 5a. , 1999, Molecular endocrinology.
[23] A. Al-Shami,et al. Granulocyte-Macrophage Colony-stimulating Factor-activated Signaling Pathways in Human Neutrophils , 1999, The Journal of Biological Chemistry.
[24] D. Yee,et al. Interleukin 4 inhibits growth and induces apoptosis in human breast cancer cells. , 1998, Cancer research.
[25] R. Puri,et al. Interleukin-13 Receptor α′ But Not α Chain: A Functional Component of Interleukin-4 Receptors , 1998 .
[26] D. Yee,et al. Insulin Receptor Substrate-1 is the Predominant Signaling Molecule Activated by Insulin-like Growth Factor-I, Insulin, and Interleukin-4 in Estrogen Receptor-positive Human Breast Cancer Cells* , 1998, The Journal of Biological Chemistry.
[27] M. Kaplan,et al. Stat Proteins Control Lymphocyte Proliferation by Regulating p27Kip1 Expression , 1998, Molecular and Cellular Biology.
[28] B. Ryffel,et al. Growth inhibition signalled through the interleukin-4/interleukin-13 receptor complex is associated with tyrosine phosphorylation of insulin receptor substrate-1. , 1996, The Biochemical journal.
[29] E. Thiel,et al. Antiproliferative effect of human interleukin-4 in human cancer cell lines: studies on the mechanism. , 1995, Leukemia & lymphoma.
[30] S. Narula,et al. Interleukin 4 retards dissemination of a human B-cell lymphoma in severe combined immunodeficient mice. , 1995, Cancer research.
[31] E. Thiel,et al. Recombinant human interleukin 4 has antiproliferative activity on human tumor cell lines derived from epithelial and nonepithelial histologies. , 1995, Cancer research.
[32] R. Puri,et al. Receptor for Interleukin 13 , 1995, The Journal of Biological Chemistry.
[33] B. Ryffel,et al. Growth inhibition of human colorectal‐carcinoma cells by interleukin‐4 and expression of functional interleukin‐4 receptors , 1994, International journal of cancer.
[34] F. Behm,et al. Interleukin-4 induces programmed cell death (apoptosis) in cases of high-risk acute lymphoblastic leukemia. , 1994, Blood.
[35] J. Rossi,et al. Antiproliferative effects of interleukin-4 on freshly isolated non-Hodgkin malignant B-lymphoma cells. , 1992, Blood.
[36] M. Toi,et al. Inhibition of colon and breast carcinoma cell growth by interleukin-4. , 1992, Cancer research.
[37] P. Leder,et al. Murine interleukin-4 displays potent anti-tumor activity in vivo , 1989, Cell.
[38] S. Rosenberg,et al. Interleukin 4 (B cell stimulatory factor 1) can mediate the induction of lymphokine-activated killer cell activity directed against fresh tumor cells , 1987, The Journal of experimental medicine.
[39] W. Paul,et al. B cell stimulatory factor-1 (interleukin 4) activates macrophages for increased tumoricidal activity and expression of Ia antigens. , 1987, Journal of immunology.
[40] D. Yee,et al. STAT6 mediates interleukin-4 growth inhibition in human breast cancer cells. , 2002, Neoplasia.
[41] Pierre Morel,et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. , 2002, The New England journal of medicine.
[42] R. Puri,et al. Overexpressed cell surface interleukin-4 receptor molecules can be successfully targeted for antitumor cytotoxin therapy. , 2001, Critical reviews in immunology.
[43] W. Paul,et al. The IL-4 receptor: signaling mechanisms and biologic functions. , 1999, Annual review of immunology.
[44] R. Puri,et al. Interleukin-13 receptor alpha' but not alpha chain: a functional component of interleukin-4 receptors. , 1998, Blood.
[45] W. Leonard,et al. Sharing of a common gamma chain, gamma c, by the IL-2, IL-4, and IL-7 receptors: implications for X-linked severe combined immunodeficiency (XSCID). , 1994, Advances in experimental medicine and biology.
[46] G. Haas,et al. Expression of high affinity interleukin-4 receptors on human renal cell carcinoma cells and inhibition of tumor cell growth in vitro by interleukin-4. , 1993, The Journal of clinical investigation.
[47] T. Grogan,et al. Effects of interleukin-4 on the in vitro growth of human lymphoid and plasma cell neoplasms. , 1990, Blood.